Global Molecular Diagnostics at the Point of Care Markets 2023-2027: New Genotypes Creating New Markets as the Developing World Drives ID Dx Growth


Dublin, May 12, 2023 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to ResearchAndMarkets.com's offering.

Learn about this market including the issues and outlooks.

The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out for five years.

Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Point of Care testing move into the Physician's Office or even the Home?

Point of Care testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance.

Industry Overview

Players in a Dynamic Market

  • Academic Research Lab
  • Diagnostic Test Developer
  • Instrumentation Supplier
  • Chemical/Reagent Supplier
  • Pathology Supplier
  • Independent Clinical Laboratory
  • Public National/regional Laboratory
  • Hospital Laboratory
  • Physicians Office Lab (POLS)
  • Audit Body
  • Certification Body

The Clinical Laboratory Market Segments

  • Traditional Market Segmentation
  • Laboratory Focus and Segmentation

Industry Structure

  • Hospital Testing Share
  • Economies of Scale
  • Hospital vs. Central Lab
  • Physician Office Lab's
  • Physician's and POCT

Market Trends

Factors Driving Growth

  • New Genotypes Creating New Markets
  • Aging Population a Boon for All Diagnostics
  • Developing World Driving ID Dx Growth
  • Point of Care - Why Centralization is Losing Steam
  • Self Testing
  • The Need for Speed

Factors Limiting Growth

  • Lower Costs
  • Infectious Disease is Declining
  • Wellness Hurts
  • Economic Growth improves Living Standards

Instrumentation, Automation and Diagnostic Trends

  • Traditional Automation and Centralization
  • The New Automation, Decentralization and Point Of Care
  • Instruments Key to Market Share
  • Bioinformatics Plays a Role
  • PCR Takes Command
  • Next Generation Sequencing Fuels a Revolution
  • NGS Impact on Pricing
  • Whole Genome Sequencing, A Brave New World
  • Companion Diagnostics Blurs Diagnosis and Treatment

Profiles of Key MDx Companies

  • Abacus Diagnostica
  • Abbott Laboratories
  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Alveo Technologies
  • Antelope Dx
  • Applied BioCode
  • Aureum Diagnostics
  • Aus Diagnostics
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • BioFire Diagnostics (bioMerieux)
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Bosch Healthcare Solutions GmbH
  • Cepheid (Danaher)
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Detect
  • Diagenode Diagnostics
  • Diasorin S.p.A.
  • Enzo Biochem
  • Eurofins Scientific
  • Fluxergy
  • Fusion Genomics.
  • Genedrive
  • Genetic Signatures
  • GenMark Dx (Roche)
  • Getlabs
  • Grip Molecular Technologies
  • Hibergene Diagnostics
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Lucira Health
  • Luminex Corp
  • LumiraDx
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech (Thermo Fisher)
  • Millipore Sigma
  • Mobidiag (Hologic)
  • Molbio Diagnostics
  • Nanomix
  • Novacyt
  • Novel Microdevices
  • Operon
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Prenetics
  • Primerdesign (Novacyt)
  • Prominex
  • Qiagen
  • QuantuMDx
  • Quidel
  • Roche Molecular Diagnostics
  • Salignostics
  • Saw Diagnostics
  • SD Biosensor
  • Seegene
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Talis Biomedical
  • Thermo Fisher Scientific Inc.
  • Veramarx
  • XCR Diagnostics
  • Zhejiang Orient Gene Biotech

Molecular Dx - Infectious Disease Recent Developments

  • Recent Developments - Importance and How to Use This Section
  • Importance of These Developments
  • How to Use This Section
  • Sherlock Biosciences Adds to Infectious Disease Dx Toolkit
  • NanoDx Prepares for Point-of-Care Commercialization
  • Paragraf to Study New POC Test to Guide Antibiotic Selection
  • MicroGEM to Expand 30-Minute RT-PCR System
  • Startup Detect to Roll Out Next-Gen Molecular Instrument
  • Diagnostics for the Real World Third-Generation POC Platform
  • Salignostics Closes Funding Round
  • Cue Health Targets DTC Market in 2022
  • Grip Molecular Developing Home Respiratory Panel
  • Mainz Biomed Developing Home ColoAlert Assay
  • MFB Fertility Closes Series A Financing Round
  • Home Test Company Prenetics to go Public
  • Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • Talis Biomedical Discusses Point-of-Care
  • Roche to Acquire GenMark Diagnostics for $1.8B
  • Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • Hologic to Acquire Mobidiag
  • Lucira Health Focuses on User Friendly Approach to Home Testing
  • Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • Mammoth Biosciences Developing Pathogen Detection Tech
  • Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • Scanogen Developing 90 Minute Infection Test
  • Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • Lumos Diagnostics Closes $15M Series A Funding



For more information about this report visit https://www.researchandmarkets.com/r/psimam

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data